Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Recruiting

• Conditions: Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)
• Interventions: Other: BIA-ALCL

• Registration Number: NCT04220970
• Lead Sponsor: The Lymphoma Academic Research Organisation

Brief Summary

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant.

Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP).

This registry is opened in France and in Belgium

Detailed Description

Not available

Study Timeline

• Study Start: 2017-06-07
• Study First Submitted: 2020-01-06
• Study First Submitted QC: 2020-01-06
• Study First Posted: 2020-01-07
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-08
• Last Update Posted: 2024-10-09
• Primary Completion: 2032-06-07
• Study Completion: 2032-06-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 150

Inclusion Criteria

• Adult patients with an anaplastic large cell lymphoma associated with breast implants

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
BIA-ALCL	BIA-ALCL	-

Primary Outcome Measures

Name	Time	Method
Overall response	13 years

Trial Locations

Locations (31)

A. Z. Sint-Jan Brugge-Oostende AV; 🇧🇪 Bruges, Belgium

Clinique Universitaire Saint LUC; 🇧🇪 Brussels, Belgium

Institut Jules Bordet; 🇧🇪 Brussels, Belgium

Universitair Ziekenhuis Brussel; 🇧🇪 Brussel, Belgium

Universitair Ziekenhuis Antwerpen; 🇧🇪 Edegem, Belgium

Cliniques Universitaires de Bruxelles - Hôpital Erasme; 🇧🇪 Bruxelles, Belgium

Universitair Ziekenhuis Gent; 🇧🇪 Gent, Belgium

CHU de Liège -Domaine Sart Tilman; 🇧🇪 Liège, Belgium

U.Z. Leuven - Campus Gasthuisberg; 🇧🇪 Leuven, Belgium

CHU UCL Namur - Site Godinne; 🇧🇪 Yvoir, Belgium

CH d Avignon - Hopital Henri Duffaut; 🇫🇷 Avignon, France

Institut Bergonié; 🇫🇷 Bordeaux, France

CHRU de Brest - Hôpital Morvan; 🇫🇷 Brest, France

Hopital Louis Pasteur; 🇫🇷 Colmar, France

APHP - Hopital Henri Mondor; 🇫🇷 Creteil, France

CHU de Dijon - Hôpital le Bocage; 🇫🇷 Dijon, France

Institut Paoli Calmettes; 🇫🇷 Marseille, France

Centre Médical la Roseraie; 🇫🇷 Lille, France

Centre Léon Bérard; 🇫🇷 Lyon, France

CH Saint-Eloi; 🇫🇷 Montpellier, France

CHU de Nantes - Hôtel Dieu; 🇫🇷 Nantes, France

CH de Pau; 🇫🇷 Pau, France

Hôpital Cochin; 🇫🇷 Paris, France

CH de Perpigan; 🇫🇷 Perpignan, France

Centre Hospitalier Lyon Sud; 🇫🇷 Pierre Bénite, France

Chu de Reims - Hopital Robert Debre; 🇫🇷 Reims, France

Centre Henri Becquerel; 🇫🇷 Rouen, France

CHRU de Strasbourg; 🇫🇷 Strasbourg, France

Centre Rene Hugenin; 🇫🇷 Saint Cloud, France

CH de Saint Malo; 🇫🇷 Saint-Malo, France

Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O); 🇫🇷 Toulouse, France